Chromatin/Epigenetics


Epigenetics is the heritable modifications in gene expression that is not associated with changes in DNA sequence. Epigenetic modifications occur mostly on DNA or on the histone octamer. There are several types of epigenetics modifications, DNA methylation by DNA-methyl transferase (DNMT) and covalent modification of histones (e.g. acetylation, methylation, phosphorylation and ubiquitination). Histone acetylation by histone acetyltransferases (HATs) is involved in transcriptional activation, whereas histone deacetylation by histone deacetylases (HDACs) is connected with transcriptional repression. Histone demethylation is associated with lysine-specific demethylase (LSD) and JmjC domain containing histone demethylase (JHDM).
The nucleosome is consisted of four histone proteins (H2A, H2B, H3, and H4), they are primary building block of chromatin. The addition and removal of specific chemical groups refers to as epigenetic marks, it regulates chromatin structure and affects gene expression. Moreover, RNA is intimately involved in the formation of a repressive chromatin state.
Epigenetic mechanism responds to environmental changes at the cellular level and thus influences cellular plasticity. Chromatin and epigenetic regulation play a significant role in the programming of the genome during development and stress response, defects in epigenetics can lead to cancer, inflammation and metabolic disorders etc.
-
A3221 Bardoxolone methylTarget: Nrf2Summary: IKK inhibitor, potent antioxidant inflammation modulator -
A3222 Baricitinib phosphateSummary: JAK1/JAK2 inhibitor -
A3246 BMN-673 8R,9S1 CitationSummary: Inactive form of BMN 673, used as negative control -
A3305 CHAPSSummary: Zwitterionic detergent for membrane proteins,nondenaturing -
A3335 Curcumin1 CitationTarget: Histone Deacetylases (HDACs)|Nrf2|Histone Acetyltransferases (HATs)|TyrosinasesSummary: Specific histone and non-histone acetyltransferase inhibitor -
A3337 CX-6258Summary: Pan-Pim kinases Inhibitor -
A3339 CYT387 sulfate saltSummary: JAK1/JAK2 inhibitor -
A3348 DaminozideTarget: KDM|PHFSummary: KDM2A inhibitor -
A3445 GSK 525768ASummary: inactive stereoisomer of I-BET-762 -
A3514 JAK2 Inhibitor V, Z3Summary: Jak2 tyrosine kinase inhibitor

